Author | David Planchard, MD, PhD | OncLive

Author | David Planchard, MD, PhD


Dr. Planchard on Dabrafenib/Trametinib Combo in Advanced NSCLC

June 15, 2016


David Planchard, MD, PhD, Department of Medical Oncology, Thoracic Unit, Institut Gustave Roussy, discusses a phase II trial examining the combination of dabrafenib and trametinib in pretreated patients with BRAF V600E-mutant advanced non–small cell lung cancer (NSCLC).